Share-based Payment Arrangement, Expense in USD of aTYR PHARMA INC from 2013 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
aTYR PHARMA INC quarterly/annual Share-based Payment Arrangement, Expense history and change rate from 2013 to Q3 2025.
  • aTYR PHARMA INC Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1.31M, a 73.8% increase year-over-year.
  • aTYR PHARMA INC Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $4.56M, a 58.4% increase year-over-year.
  • aTYR PHARMA INC annual Share-based Payment Arrangement, Expense for 2024 was $2.99M, a 15% increase from 2023.
  • aTYR PHARMA INC annual Share-based Payment Arrangement, Expense for 2023 was $2.6M, a 20.7% increase from 2022.
  • aTYR PHARMA INC annual Share-based Payment Arrangement, Expense for 2022 was $2.15M, a 33.5% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

aTYR PHARMA INC Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $4.56M $1.31M +$555K +73.8% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025
Q2 2025 $4.01M $1.31M +$578K +79.5% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025
Q1 2025 $3.43M $1.18M +$438K +59.2% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025
Q4 2024 $2.99M $770K +$111K +16.8% 01 Oct 2024 31 Dec 2024 10-K 13 Mar 2025
Q3 2024 $2.88M $752K +$88K +13.3% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025
Q2 2024 $2.79M $727K +$69K +10.5% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025
Q1 2024 $2.72M $740K +$121K +19.5% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025
Q4 2023 $2.6M $659K +$54K +8.93% 01 Oct 2023 31 Dec 2023 10-K 13 Mar 2025
Q3 2023 $2.55M $664K +$49K +7.97% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024
Q2 2023 $2.5M $658K +$141K +27.3% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024
Q1 2023 $2.36M $619K +$202K +48.4% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024
Q4 2022 $2.15M $605K +$191K +46.1% 01 Oct 2022 31 Dec 2022 10-K 13 Mar 2025
Q3 2022 $1.96M $615K +$173K +39.1% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q2 2022 $1.79M $517K +$119K +29.9% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023
Q1 2022 $1.67M $417K +$57K +15.8% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023
Q4 2021 $1.61M $414K +$74K +21.8% 01 Oct 2021 31 Dec 2021 10-K 14 Mar 2024
Q3 2021 $1.54M $442K +$118K +36.4% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022
Q2 2021 $1.42M $398K +$20K +5.29% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022
Q1 2021 $1.4M $360K -$63K -14.9% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022
Q4 2020 $1.47M $340K -$85K -20% 01 Oct 2020 31 Dec 2020 10-K 14 Mar 2023
Q3 2020 $1.55M $324K +$46K +16.5% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021
Q2 2020 $1.5M $378K -$131K -25.7% 01 Apr 2020 30 Jun 2020 10-Q 11 Aug 2021
Q1 2020 $1.64M $423K -$148K -25.9% 01 Jan 2020 31 Mar 2020 10-Q 14 May 2021
Q4 2019 $1.78M $425K -$177K -29.4% 01 Oct 2019 31 Dec 2019 10-K 15 Mar 2022
Q3 2019 $1.96M $278K -$412K -59.7% 01 Jul 2019 30 Sep 2019 10-Q 13 Nov 2020
Q2 2019 $2.37M $509K -$702K -58% 01 Apr 2019 30 Jun 2019 10-Q 13 Aug 2020
Q1 2019 $3.07M $571K -$357K -38.5% 01 Jan 2019 31 Mar 2019 10-Q 12 May 2020
Q4 2018 $3.43M $602K -$2.53M -80.8% 01 Oct 2018 31 Dec 2018 10-K 24 Mar 2021
Q3 2018 $5.96M $690K -$499K -42% 01 Jul 2018 30 Sep 2018 10-Q 14 Nov 2019
Q2 2018 $6.46M $1.21M +$28K +2.37% 01 Apr 2018 30 Jun 2018 10-Q 14 Aug 2019
Q1 2018 $6.44M $928K -$349K -27.3% 01 Jan 2018 31 Mar 2018 10-Q 14 May 2019
Q4 2017 $6.78M $3.14M +$1.98M +172% 01 Oct 2017 31 Dec 2017 10-K 26 Mar 2020
Q3 2017 $4.8M $1.19M -$35K -2.86% 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018
Q2 2017 $4.84M $1.18M -$190K -13.8% 01 Apr 2017 30 Jun 2017 10-Q 14 Aug 2018
Q1 2017 $5.03M $1.28M -$3K -0.23% 01 Jan 2017 31 Mar 2017 10-Q 15 May 2018
Q4 2016 $5.03M $1.15M -$1.24M -51.7% 01 Oct 2016 31 Dec 2016 10-K 26 Mar 2019
Q3 2016 $6.26M $1.22M +$174K +16.6% 01 Jul 2016 30 Sep 2016 10-Q 14 Nov 2017
Q2 2016 $6.09M $1.37M +$557K +68.3% 01 Apr 2016 30 Jun 2016 10-Q 14 Aug 2017
Q1 2016 $5.53M $1.28M +$677K +112% 01 Jan 2016 31 Mar 2016 10-Q 11 May 2017
Q4 2015 $4.86M $2.39M +$1.38M +137% 01 Oct 2015 31 Dec 2015 10-K 20 Mar 2018
Q3 2015 $3.48M $1.05M +$576K +122% 01 Jul 2015 30 Sep 2015 10-Q 14 Nov 2016
Q2 2015 $2.9M $816K +$651K +395% 01 Apr 2015 30 Jun 2015 10-Q 10 Aug 2016
Q1 2015 $2.25M $603K +$457K +313% 01 Jan 2015 31 Mar 2015 10-Q 11 May 2016
Q4 2014 $1.79M $1.01M 01 Oct 2014 31 Dec 2014 10-K 16 Mar 2017
Q3 2014 $474K 01 Jul 2014 30 Sep 2014 10-Q 10 Nov 2015
Q2 2014 $165K 01 Apr 2014 30 Jun 2014 10-Q 12 Aug 2015
Q1 2014 $146K 01 Jan 2014 31 Mar 2014 10-Q 18 Jun 2015

aTYR PHARMA INC Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $2.99M +$389K +15% 01 Jan 2024 31 Dec 2024 10-K 13 Mar 2025
2023 $2.6M +$446K +20.7% 01 Jan 2023 31 Dec 2023 10-K 13 Mar 2025
2022 $2.15M +$540K +33.5% 01 Jan 2022 31 Dec 2022 10-K 13 Mar 2025
2021 $1.61M +$149K +10.2% 01 Jan 2021 31 Dec 2021 10-K 14 Mar 2024
2020 $1.47M -$318K -17.8% 01 Jan 2020 31 Dec 2020 10-K 14 Mar 2023
2019 $1.78M -$1.65M -48% 01 Jan 2019 31 Dec 2019 10-K 15 Mar 2022
2018 $3.43M -$3.35M -49.4% 01 Jan 2018 31 Dec 2018 10-K 24 Mar 2021
2017 $6.78M +$1.76M +34.9% 01 Jan 2017 31 Dec 2017 10-K 26 Mar 2020
2016 $5.03M +$173K +3.56% 01 Jan 2016 31 Dec 2016 10-K 26 Mar 2019
2015 $4.86M +$3.07M +171% 01 Jan 2015 31 Dec 2015 10-K 20 Mar 2018
2014 $1.79M +$1.64M +1055% 01 Jan 2014 31 Dec 2014 10-K 16 Mar 2017
2013 $155K 01 Jan 2013 31 Dec 2013 10-K 30 Mar 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.